Updated hourlyHourly refreshFri, Sep 4, 2026
Finance · Healthcare
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..
Aug 28 · 11:03·PR-Inside
SaaS · Healthcare
VMRD, Inc. is thrilled to share the launch of their exciting new test for horse-side measurement of insulin in horses. Run on the same palm-sized reader as VMRD SAA and Foal IgG, this highly portable multi-functional testing platform embodies VMRD’s vision of improving animal health through high-quality, practical diagnostics. Equine Metabolic Syndrome and insulin dysregulation are incredibly common in the equine [PR.com]
Aug 28 · 11:02·PR.com
Healthcare
Vibrational therapist and educator brings sound healing, breathwork and integrative mentorship to the organization's expanding provider network
Aug 28 · 11:00·Newswire.com
Healthcare
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its established A1C and weight loss benefits It is estimated that as many as one in...
Aug 28 · 11:00·PR Newswire
Healthcare
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly...
Aug 28 · 11:00·PR Newswire
Finance · Healthcare
VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 3,300,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.06 per common share.
Aug 28 · 10:30·GlobeNewswire
Finance · SaaS
HONG KONG, August 28, 2026 - (ACN Newswire) - Cryofocus Medtech (Shanghai) Co., Ltd. (“Cryofocus” or the “Company,” stock code: 6922.HK), a leading innovative medical device platform specializing in minimally-invasive interventional cryotherapy, today announced its interim results for the six months ended June 30, 2026. During the Reporting Period, the Company continued to expand its product pipeline, with a significant 37.9% narrowing of its loss for the period to RMB 16.9 million. Gross profit margin improved to 68.5% from 67.1% in the same period last year, while cash and cash equivalents surged 69.2% to RMB 59.3 million compared to the end of 2025, underscoring enhanced operational quality and financial resilience.
Product Pipeline Continues to Expand, Commercial Footprint Widens
As a pioneer in the field of minimally-invasive interventional cryotherapy in China, Cryofocus has established a comprehensive product portfolio covering both vascular intervention and natural orifice transluminal endoscopic surgery (NOTES). As of June 30, 2026, the Company had a total of 25 products and product candidates, of which 11 had been commercialized. These include the Atrial Fibrillation Cryoablation System, Malignant Stenosis Cryoablation System, Cryoadhesion System, Bladder Cryoablation System, and Pulmonary Nodule Localization Needle, among others.
In January 2026, the Company’s Endoscopic Additional Working Channel Catheter received approval from the Zhejiang Medical Products Administration, further enriching its commercial product matrix. Meanwhile, several high-value product candidates have entered the critical confirmatory clinical trial stage and are expected to receive approvals sequentially between 2027 and 2029. These include:
- Vascular Intervention:
Cryofocus Renal Denervation System (Cryo-RDN System): Designed to be the world’s first cryoablation product specifically targeting hypertension. It was granted Breakthrough Device designation by the U.S. FDA in December 2022.
- Respiratory Intervention:
COPD Cryospray System, Peri-Pulmonary Nodule Cryoablation System, Asthma Cryoablation System, and Benign Stenosis Cryoablation System: These products form a matrix of investigational devices targeting the same hospital department. As they receive approvals in the coming period, the synergistic effect of this product matrix is expected to amplify.
The Company’s R&D team comprises 40 professionals. As of June 30, 2026, Cryofocus held 179 patents and 35 patent applications domestically and internationally, continuously deepening its technological moat.
Loss Narrows Significantly, Gross Margin Improves Against Headwinds
Alongside steady progress in its product pipeline, the Company delivered impressive financial metrics. For the first half of 2026, Cryofocus recorded revenue of RMB 40.7 million and gross profit of RMB 27.9 million. The loss for the period amounted to RMB 16.9 million, a decrease of RMB 10.3 million or 37.9% from RMB 27.2 million in the same period of 2025.
Against the backdrop of an active adjustment in revenue scale, the Company’s overall gross profit margin rose from 67.1% to 68.5%, primarily driven by process improvements and optimizations for certain products. This indicates that structural improvements in the product mix and enhanced production efficiency have effectively offset the impact of revenue fluctuations on profitability.
Comprehensive Cost Optimization Boosts Operating Efficiency Significantly
The substantial narrowing of losses was underpinned by the Company’s holistic cost control measures:
- Administrative expenses decreased by 34.0% from RMB 33.7 million to RMB 22.3 million, mainly due to reductions in staff costs and share-based payments.
- Selling and distribution expenses fell by 14.5% from RMB 9.2 million to RMB 7.8 million.
- Research and development expenses declined by 15.1% from RMB 17.9 million to RMB 15.2 million.
- Finance costs dropped by 22.7% from RMB 1.1 million to RMB 0.8 million.
Furthermore, other income and gains surged over 550% from RMB 0.5 million to RMB 3.2 million, primarily attributable to an increase in government grants. The combined effect of comprehensive cost optimization and growth in non-recurring income enabled the Company to achieve a sharp compression of losses despite a temporary decline in revenue.
Cash Reserves Surge 69.2%, Strengthening Capital Position
As of June 30, 2026, the Company’s cash and cash equivalents stood at RMB 59.3 million, an increase of RMB 24.2 million or 69.2% from RMB 35.0 million as of December 31, 2025. This growth was mainly driven by the completion of an H-share placing in January 2026, under which the Company issued 5,595,000 H-shares and raised net proceeds of approximately HK$29.73 million.
Additionally, the Company’s current ratio improved from 1.5 to 1.7, the quick ratio rose from 1.0 to 1.2, and the gearing ratio decreased from 64.7% to 61.8%, reflecting enhanced short-term solvency and overall financial safety.
Outlook: Committed to Becoming a Global Minimally-Invasive Interventional Cryotherapy Medical Device Platform, Bringing Benefits to Patients and Physicians Worldwide
In the first half of 2026, the Company proactively adjusted its sales strategy to align with evolving industry demands, leading to a temporary dip in revenue. However, earnings quality improved markedly, signaling a positive trend of “structural revenue adjustment with clear profit elasticity.”
Looking ahead, the Company will:
- Rapidly advance the clinical development and commercialization of its product candidates based on cryotherapy technology;
- Continue to focus on minimally-invasive interventional cryotherapy and further expand its product portfolio leveraging its technology platform;
- Persistently research and develop various underlying and supporting technologies; and
- Selectively expand its global footprint.
With high-value products such as the Cryofocus Renal Denervation System, COPD Cryospray System, and Peri-Pulmonary Nodule Cryoablation System entering the regulatory submission and launch cycle, coupled with a significantly strengthened cash position and continuous loss reduction, Cryofocus is steadily accelerating toward its vision of becoming a “global minimally-invasive interventional cryotherapy medical device platform.”
Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Aug 28 · 10:17·mlpr-acnnewswire
Finance · Healthcare
Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA review
Aug 28 · 10:17·GlobeNewswire
Finance · AI
HONG KONG, August 28, 2026 - (ACN Newswire) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its interim results for the six months ended 30 June 2026 (the “Period”) with interim contracts-in-hand continuing their record-setting performance, providing a solid foundation for the business over the next three years and beyond.
Business Highlights
- Interim contracts-in-hand surged by 34.9% to HK$17,649.3 million, attaining yet another record high
- Revenue was HK$3,036.6 million, up by 5.7%, primarily driven by steady project execution in the Building Services and Environmental Engineering segments
- Profit attributable to owners of the Company increased 88.1% to HK$152.0 million. The increase was partly attributable to the disposal of an approximately 3% equity stake in Nanjing Canatal Data-Centre Environmental Tech Co., Ltd.(Shanghai Stock Code: 603912)
- The Group maintained a strong cash position, with bank balances and cash at HK$1,214.1 million
- Interim dividend amounted to HK4.9 cents per share, with a year-on-year increase of more than 88%
- Artificial Intelligence (AI) has been integrated into Analogue’s interconnected smart ecosystem to create value for customers, by realising a smart platform for buildings, and advanced operational solutions for water and sewage treatment, as evidenced by the prestigious accolades across both the research and adoption categories at the inaugural Construction Industry Council AI Award 2026 and at the ASHRAE Region XIII Technology Award 2026
Chairman Dr Mak Kin Wah said, “Building on our outstanding achievement of record-high contracts-in-hand in 2025, the Group maintained steady business performance in the first half of 2026. By integrating research, development and application of AI technologies, we have achieved optimised operations and enhanced quality that earn wide recognition from the industry. Committed to innovation, the Group will further promote integration of AI, Digital Twin, and the Internet of Things (“IoT”), develop cross-technology integrated solutions, and enhance performance in engineering operations, safety, and sustainable development, to create greater value for clients.”
“Our commitment to business ethics, quality, safety, health and environmental sustainability remains at the core of everything we do, guiding our decisions, shaping our culture, and contributing to a more sustainable future."
Business Review: Building Services
- This segment remains the largest revenue contributor, with revenue reaching HK$1,649.6 million.
- Interim contracts-in-hand reached a record-high level of HK$7,996.6 million, with order intake standing at HK$1,348.8 million and many of the tenders submitted in the Period due for determination in phases later this year.
- Many projects in the Northern Metropolis, including Fanling and Kwu Tung housing projects and various hospitals, were prioritised for commencement and progress in execution.
- The Group’s expertise in Building Information Modelling (BIM), Design for Manufacture and Assembly (DfMA) and Modular Integrated Mechanical, Electrical and Plumbing (MiMEP) continued to gain market traction and helped secure major contracts.
- Leveraging our comprehensive interdisciplinary capacity and new engineering techniques, this segment maintained our industry leadership, and was broadening our market reach to different parts of Asia.
Environmental Engineering
- This segment achieved record-high interim contracts-in-hand, which surged substantially by 78.3% year-on-year to HK$8,164.2 million. Order intake stood at HK$910.1 million with active ongoing tendering activities and many of the tenders submitted in the period due for determination in phases later this year. Segment revenue increased by 17.2% year-on-year or HK$123.2 million.
- A number of projects, including a landmark engineering contract to reprovision critical sewage treatment works to caverns, were prioritised for commencement and execution.
- New term contracts for sewage and E&M systems were also added to the recurrent operation, maintenance, and facility management services provided by the segment.
- By deploying AI and Digital Twin under our industry-recognised AlgoWater® brand, the segment continued to strengthen our industry leading position by advancing in intelligent automation, predictive asset management, and real-time process optimisation that significantly enhance treatment efficiency and energy savings for industrial operations.
- Continued to pursue project opportunities with partners in the Chinese Mainland and different parts in Asia and Europe.
Information, Communications and Building Technologies (“ICBT”)
- Segment revenue amounted to HK$290.9 million. Contracts-in-hand totalled HK$830.8 million. Order intake was HK$269.9 million.
- As an early mover backed by its own R&D capability and extensive project experience, this segment was well positioned to continue to advance innovation. A robust digital foundation was established through the Digital Plant and Centralised Management Platform (CMP) that enables real-time insights and data-driven decisions.
- Integration of IoT and advanced Building Management System (BMS) under our acclaimed DigiFusion® AI Smart Building Platform delivers optimised operational efficiency and enhanced tenant experiences in smart buildings and city infrastructure, as well as resource circularity for our clients.
Lifts and Escalators
- Revenue and contracts-in-hand were at HK$255.9 million and HK$657.7 million respectively.
- Order intake totalled HK$278.4 million, with ongoing tendering activities in different parts of the world.
- Transel Elevator & Electric Inc. (TEI), the associate company in the United States, maintained its strength as one of the largest independent lift and escalator companies in New York and continued to expand in the southeastern part of the country, strengthening our market positioning and future growth.
- Competitiveness was strengthened with enhanced automation in production lines and strict quality controls, to anchor the end-to-end business model from design, through manufacturing, to installation and maintenance services.
- The product portfolio was broadened in line with the expanding international market reach and enhanced with next-generation product innovations.
For further details of the 2026 Interim Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.
About Analogue Holdings Limited
Established in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.
The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (Shanghai Stock Code: 603912), specialises in precision environmental control technologies and related energy-saving and temperature control equipment for data centres.
Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Aug 28 · 10:11·mlpr-acnnewswire
Healthcare
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting...
Aug 28 · 10:03·PR Newswire
Healthcare · Energy
Best Seller Publishing announces the release Michele Rase's new book, “Declutter Your Home, Declutter Your Life.” The book is currently free and available for download on Amazon for one more day. - - “Declutter Your Home, Declutter Your Life” is about creating a home that gives you energy instead of quietly draining it. Life and Health Coach Michele Rase explores how clutter can create emotional and mental noise, especially when tied to memories, guilt, unfinished decisions, or past... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359243
Aug 28 · 10:00·WebWire
SaaS · Healthcare
Partnership will explore new healthcare opportunities arising from the link between sleep disorders and cardiovascular disease Collaboration to span the integration of sleep data with cardiovascular risk factors, academic initiatives, and more Philips' health technology expertise and...
Aug 28 · 10:00·PR Newswire